EFFECT OF PENTOXIFYLLINE IN PATIENTS WITH IRRITABLE BOWEL SYNDROME (IBS).

Conditions: IRRITABLE BOWEL SYNDROME (IBS) generates tomach pain and changes in depositions number and consistency. IBS has a high prevalence in Digestive consultations. In spite of this, we haven´t good treatments to avoid cronic and recurrents symptoms.
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]

Registration Number: EUCTR2010-024028-24-ES

Lead Sponsor: Hospital Universitario de Canarias

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Authorised-recruitment may be ongoing or finished

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

P atients from 18 to 65 years old and with capacity to give informed consent.
The patients with IBS are belong that patients who come to Digestive consultation from our center.
Patients must have a monitoring at least 6 months before the inclussion.
Achive the Roma III criterions for IBS (Gastroenterology 2006;130:1377-90) with moderate-severe gravity according to Francis modificated scale.
Patients could not have any alergic pathology or gastrointestinals illness.
Women with fertile age no pregnant (proven blood or urine test in visit of selection) and use methods of contraception at least from 14 days before first dose of medicine until 14 days after last dose of medicine.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 59
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Patients can not take Salicylates, NSAIDs, antibiotics,anticholinergic, Opiates or any other medication or product
use for diarrea sintomatic treathment two weeks before biopsia. Besides, others medications as corticoid, antihistamine or immunosuppressives can not be taken 3 months before the colon biopsia.
Patients who had recibed radiotherapy or chemotherapy 6 months before the study.
Alergic reactions to pentoxifiline, pregnancy, kidney or hepatic severe failure or any mental or legal disability to sign informed consent .
Pregnant or while breastfeeding.
All cases where medicine in research is contraindicated by medicine technical data

Study & Design

Study Type: Interventional clinical trial of medicinal product

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: Determine the therapeutic effectiveness of treatment with oral pentoxifiline in the severity and the clinic evolution of patient with IBS.;Secondary Objective: Research the effect os treatment with pentoxifiline;Primary end point(s): Main variable will be the assessment of IBS clinic evolution and severity.;Timepoint(s) of evaluation of this end point: 1 year

Secondary Outcome Measures